Werewolf Therapeutics, Inc.
General ticker "HOWL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $48.9M (TTM average)
Werewolf Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -15.1%.
Estimated limits based on current volatility of 5.7%: low 0.43$, high 0.49$
Factors to consider:
- Total employees count: 46 (-2.1%) as of 2024
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Reimbursement and pricing pressures, Litigation risks, Operational and conduct risks
- Current price 14.9% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.50$, 1.63$]
- 2026-12-31 to 2027-12-31 estimated range: [0.61$, 1.85$]
Financial Metrics affecting the HOWL estimates:
- Positive: with PPE of -0.5 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: 19.24 < Shareholder equity ratio, % of 35.74 <= 42.59
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term HOWL quotes
Long-term HOWL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $19.94MM | $1.89MM | $0.00MM |
| Operating Expenses | $60.45MM | $75.48MM | $60.68MM |
| Operating Income | $-40.50MM | $-73.59MM | $-60.68MM |
| Non-Operating Income | $3.13MM | $3.08MM | $-0.14MM |
| Interest Expense | $3.14MM | $4.66MM | $5.27MM |
| R&D Expense | $41.78MM | $56.43MM | $44.83MM |
| Income(Loss) | $-37.37MM | $-70.52MM | $-60.82MM |
| Net Income(Loss)* | $-37.37MM | $-70.52MM | $-60.82MM |
| Stockholders Equity | $111.37MM | $73.39MM | $24.80MM |
| Assets | $174.83MM | $126.93MM | $69.40MM |
| Operating Cash Flow | $-32.61MM | $-56.19MM | $-60.29MM |
| Capital expenditure | $0.77MM | $0.25MM | $0.00MM |
| Investing Cash Flow | $-0.77MM | $-0.25MM | $0.00MM |
| Financing Cash Flow | $58.43MM | $13.08MM | $6.03MM |
| Earnings Per Share** | $-1.05 | $-1.63 | $-1.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.